Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
Landmark molecular profiling efforts have identified multiple targetable alterations in cholangiocarcinoma. Among the molecular-driven subsets of cholangiocarcinoma, targeting the fibroblast growth factor receptor (FGFR) has shown promise and represents the first targeted therapy to be approved in t...
Main Authors: | Patrick C. Lee, Andrew Hendifar, Arsen Osipov, May Cho, Daneng Li, Jun Gong |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/7/1706 |
Similar Items
-
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01) -
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
by: Anuhya Kommalapati, et al.
Published: (2021-06-01) -
Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos
by: Maria P. Kotini, et al.
Published: (2021-12-01) -
Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
by: Gregor Vlacic, et al.
Published: (2019-09-01) -
Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
by: Oleg Alekseev, et al.
Published: (2021-04-01)